166 related articles for article (PubMed ID: 32738418)
1. Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors.
Umemura S; Zhu J; Chahine JJ; Kallakury B; Chen V; Kim IK; Zhang YW; Goto K; He Y; Giaccone G
Lung Cancer; 2020 Sep; 147():221-228. PubMed ID: 32738418
[TBL] [Abstract][Full Text] [Related]
2. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
3. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
4. Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors.
Chen Y; Zhang Y; Chai X; Gao J; Chen G; Zhang W; Zhang Y
Biomed Res Int; 2018; 2018():5830547. PubMed ID: 29850538
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses.
Ishihara S; Okada S; Ogi H; Kodama Y; Shimomura M; Tsunezuka H; Itoh K; Marx A; Inoue M
Lung Cancer; 2020 Jul; 145():40-47. PubMed ID: 32402921
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinicopathological roles of programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors: A meta-analysis.
Koh HM; Jang BG; Lee HJ; Hyun CL
Thorac Cancer; 2020 Nov; 11(11):3086-3098. PubMed ID: 32926538
[TBL] [Abstract][Full Text] [Related]
7. High levels of expression of Trop-2 in thymic epithelial tumors.
Yeung V; Zaemes J; Yeh J; Giancarlo C; Ahn J; Reuss JE; Kallakury BV; Liu SV; Duttargi A; Khan G; Kim C
Lung Cancer; 2023 Oct; 184():107324. PubMed ID: 37573703
[TBL] [Abstract][Full Text] [Related]
8. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
10. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8
Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J
Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897
[TBL] [Abstract][Full Text] [Related]
11. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
12. Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines.
Owaki R; Deguchi T; Konnai S; Maekawa N; Okagawa T; Hosoya K; Kim S; Sunaga T; Okumura M
Vet Comp Oncol; 2023 Jun; 21(2):279-290. PubMed ID: 36802270
[TBL] [Abstract][Full Text] [Related]
13. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
14. Tumor immunity is related to
Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
[TBL] [Abstract][Full Text] [Related]
15. CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
Wang H; Yan Z; Hao J; Yang B; Wang J; Yi L; Wang X; Li S; Zhang H; Zhang S
Thorac Cancer; 2019 Dec; 10(12):2225-2235. PubMed ID: 31625289
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.
Berardi R; Goteri G; Brunelli A; Pagliaretta S; Paolucci V; Caramanti M; Rinaldi S; Refai M; Pompili C; Morgese F; Torniai M; Marcantognini G; Ricci G; Mazzanti P; Onofri A; Bianchi F; Sabbatini A; Cascinu S
Expert Opin Ther Targets; 2020 Sep; 24(9):937-943. PubMed ID: 32662701
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
Bedekovics J; Beke L; Mokanszki A; Szilagyi S; Mehes G
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):1-9. PubMed ID: 30499814
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.
Yee D; Shah KM; Coles MC; Sharp TV; Lagos D
J Biol Chem; 2017 Dec; 292(50):20683-20693. PubMed ID: 29066622
[TBL] [Abstract][Full Text] [Related]
20. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
Katsuya Y; Horinouchi H; Asao T; Kitahara S; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Watanabe S; Tsuta K; Ohe Y
Lung Cancer; 2016 Sep; 99():4-10. PubMed ID: 27565906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]